RPRX ROYALTY PHARMA

Ownership history in GENERAL ATLANTIC, L.P.  ·  22 quarters on record

This page tracks every 13F SEC filing in which GENERAL ATLANTIC, L.P. reported a position in ROYALTY PHARMA (RPRX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
2.18% (2020 Q2)
Avg. % of fund
0.96%
First filed
2020 Q2
Last filed
2025 Q3
Quarters held
22
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 UNCHANGED 1,500,000 0% 1.59% $52.9M $34.90
2025 Q2 UNCHANGED 1,500,000 0% 1.49% $54.0M $35.43
2025 Q1 UNCHANGED 1,500,000 0% 1.57% $46.7M $30.41
2024 Q4 UNCHANGED 1,500,000 0% 1.36% $38.3M $24.75
2024 Q3 UNCHANGED 1,500,000 0% 1.21% $42.4M $27.23
2024 Q2 UNCHANGED 1,500,000 0% 1.24% $39.6M $25.18
2024 Q1 UNCHANGED 1,500,000 0% 1.06% $45.6M $28.79
2023 Q4 UNCHANGED 1,500,000 0% 0.60% $42.1M $26.44
2023 Q3 UNCHANGED 1,500,000 0% 0.63% $40.7M $25.35
2023 Q2 UNCHANGED 1,500,000 0% 0.73% $46.1M $28.52
12 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    RPRX price (monthly, adj. close)
← Back to GENERAL ATLANTIC, L.P. Holdings